- Rocket Doctor AI’s U.S. based subsidiary, Treatment.com Inc., in collaboration with Rush River Research, has been awarded a US $2 million NIH SBIR Phase II grant from the National Institute on Minority Health and Health Disparities (National Institutes of Health).
- The two-year project will advance an AI-powered, culturally sensitive family medical history tool to improve early diagnosis and preventive care for all populations.
- The award provides Treatment with over US $500,000 in support to enhance its Global Library of Medicine (GLM) and integrate advanced AI for more equitable, accurate, and human-centered healthcare.
Bloomington, Minneapolis, Oct. 15, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced that its US-based subsidiary, Treatment.com Inc. (“Treatment”) in collaboration with Rush River Research has been awarded a highly competitive NIH Small Business Innovation Research (SBIR) grant from the National Institute on Minority Health and Health Disparities (National Institutes of Health). This Phase 2 award advances the collection of culturally sensitive family medical histories using the application of Artificial Intelligence (AI).
The US $2 Million two-year award supports the further development and commercialization of important research advances that were developed in Phase 1. With experts drawn from across the United States and with the additional contribution of engineering and design excellence from Rush River Research, the award will provide Treatment with over US $500,000 to further develop and integrate innovative approaches that enhance Treatment’s handling of medical history data across several commercial platforms.
“We are excited to continue this important work with Treatment and our partners following the success of Phase I,” said Julie Lundstrom, Co-founder, Rush River Research. “Our goal is to help families have informed conversations about their family health history and better understand the important role it plays in their overall wellbeing. This project shows how thoughtful design, cultural awareness, community insight, and collaboration can combine with AI innovation to create medical technologies that are more effective and accessible for everyone.”
Phase II awards are highly competitive, following a rigorous peer-review process at the NIH that reflects both scientific merit and real-world potential. This award focuses on collecting and applying family health history to improve the diagnosis and treatment of disease, particularly among African Americans who face higher mortality from heart disease, stroke, cancer, diabetes, and other conditions strongly influenced by family history. By incorporating cultural perspectives, rigorous usability and literacy testing, and engaging community input – the project will support the more effective use of family health history in preventive care, early diagnosis, targeted screening, and lifestyle changes. While the project is focused on African-American communities, the approaches and insights gained will be applied to improve the value of the family health history for improving the health of all families.
Treatment collaborated with Rush River Research during the initial phase of the project. Building on Rush River Research’s deep technical, research, and design expertise, Treatment looks forward to jointly advancing the valuable findings of Phase 1 to further leverage its proprietary Global Library of Medicine (GLM) and suite of AI-driven healthcare solutions that the GLM supports. Both organizations share a commitment to universally improving access to care and ensuring that healthcare providers are equipped with the most effective digital tools to support patients and improve clinical outcomes.
Dr. Kevin Peterson, Founder and Chief Medical Officer, said “We’re excited to deepen our collaboration with Rush River Research and apply our next generation AI technologies to make a tangible difference across all communities. Conventional AI models can overlook the realities of historical, genetic, and cultural differences. This important work helps bridge that gap, advancing our understanding of how health is shaped by the relationships, families, and communities where people live. By combining the complementary expertise of Rush River Research and Treatment, we are creating AI systems that are more modern, more accurate and ultimately more human-centered.”
About Rush River Research
Rush River Research translates innovative ideas into practical healthcare solutions. With expertise in engineering, software development, and medical technology project management, the team has guided projects from concept to product. Rush River Research also brings extensive experience in NIH grant writing and management, applying human-centered design and clinical collaboration to create technologies that reflect community needs, advance healthcare, and are positioned for real-world adoption.
To learn more about Rush River Research, go to : www.rushriverresearch.com
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs and specialists to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching disenfranchised, rural, and remote communities who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
http://www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Kevin A Peterson, CMO, Treatment.com Inc.
kevin.peterson@treatment.com
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.’s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
